Eric Ende is listed as a director on 1 SEC Form D filing by 1 issuer in Feb 2025: Matinas BioPharma Holdings, Inc. (Bedminster, NJ — biotechnology — 2025; $15.5M reported sold to 270 investors).
What this means One deal on file with the SEC, filed Feb 2025. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Evelyn D'An (1 shared filing), Jerome Jabbour (1 shared filing), Keith Kucinski (1 shared filing), Matthew Wikler (1 shared filing), Natasha Giordano (1 shared filing) and 1 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Eric. Each name links to their own page.
The issuer belongs to the sponsor group Matinas Biopharma (2 issuers, $2.65M reported sold, 2013–2025).
What this means A sponsor group is one team that sets up a new company for each deal. Matinas Biopharma has 2 companies on file and $2.65M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 1 public filing for Eric Ende and found 2 differences: No amendment in the last 12 months on an offering that may still be open; Same name, different state: "Eric Jason Ende" (FL) is a separate record.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.